|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.38 USD | -1.44% |
|
+4.55% | -13.39% |
| 07-30 | Celcuity Announces FDA Approval And NCCN Guidelines Inclusion For REVTORPYK In Combination With Fulvestrant With Or Without Palbociclib | CI |
| 07-15 | Celcuity Inc. - Special Call |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bullish |
| Resistance | 95.93 | 111.05 | 138.23 |
| Spread/Res. | -9.96% | -22.22% | -37.51% |
| Spread/Supp. | +5.00% | +5.00% | +15.92% |
| Support | 82.27 | 82.27 | 74.52 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- CELC Stock
- Charts Celcuity Inc.
Select your edition
All financial news and data tailored to specific country editions
